BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1252 related articles for article (PubMed ID: 11070098)

  • 1. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Esteller M; Garcia-Foncillas J; Andion E; Goodman SN; Hidalgo OF; Vanaclocha V; Baylin SB; Herman JG
    N Engl J Med; 2000 Nov; 343(19):1350-4. PubMed ID: 11070098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
    Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics--teaching old drugs new tricks.
    Weinstein JN
    N Engl J Med; 2000 Nov; 343(19):1408-9. PubMed ID: 11070107
    [No Abstract]   [Full Text] [Related]  

  • 5. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.
    Blanc JL; Wager M; Guilhot J; Kusy S; Bataille B; Chantereau T; Lapierre F; Larsen CJ; Karayan-Tapon L
    J Neurooncol; 2004 Jul; 68(3):275-83. PubMed ID: 15332332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas.
    Komine C; Watanabe T; Katayama Y; Yoshino A; Yokoyama T; Fukushima T
    Brain Pathol; 2003 Apr; 13(2):176-84. PubMed ID: 12744471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Ali-Osman F; Srivenugopal K; Sawaya R
    N Engl J Med; 2001 Mar; 344(9):687; author reply 687-8. PubMed ID: 11229339
    [No Abstract]   [Full Text] [Related]  

  • 10. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
    Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Buckner JC; Moynihan TJ
    N Engl J Med; 2001 Mar; 344(9):686; author reply 687-8. PubMed ID: 11229337
    [No Abstract]   [Full Text] [Related]  

  • 12. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
    Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
    Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
    Pollack IF; Hamilton RL; Sobol RW; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL
    J Clin Oncol; 2006 Jul; 24(21):3431-7. PubMed ID: 16849758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Quinn DI
    N Engl J Med; 2001 Mar; 344(9):686; author reply 687-8. PubMed ID: 11229338
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.
    Jaeckle KA; Eyre HJ; Townsend JJ; Schulman S; Knudson HM; Belanich M; Yarosh DB; Bearman SI; Giroux DJ; Schold SC
    J Clin Oncol; 1998 Oct; 16(10):3310-5. PubMed ID: 9779706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
    Schlegel U
    N Engl J Med; 2001 Mar; 344(9):686-7; author reply 687-8. PubMed ID: 11229336
    [No Abstract]   [Full Text] [Related]  

  • 18. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.